Nitroimidazoles as Hypoxia-Mediated Drugs in Cancer Chemotherapy

  • I. J. Stratford
  • G. E. Adams
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 42)


There is abundant evidence that human tumours, even of quite small size (2 mm) contain a significant proportion of cells that are deficient in oxygen CD. These hypoxic cells are radiation-resistant and are believed to limit in some instances the effectiveness of the treatment of cancer by radiotherapy. Several of the papers presented in this Conference have discussed how nitroimidazoles might be used to overcome this problem by specifically increasing the radiation sensitivity of the resistant hypoxic cells. This paper is concerned, however, with the potential use of nitroimidazoles in cancer chemotherapy.


Cytotoxic Drug Hypoxic Cell Enhancement Ratio Radiation Sensitizer Chinese Hamster Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    W. U. Shipley, J. A. Stanley and G. G. Steel, Tumour size dependency on the radiation response of the Lewis Lung carcinoma, Cancer Res. 35: 2488 (1975).PubMedGoogle Scholar
  2. 2.
    B. Dixon, J. V. Moore and H. Speakman, Radiobiological hypoxia of a transplanted rat tumour and the effect of treatment with cyclophosphamide, Eur. J. Cancer 14:1383 (1978).PubMedCrossRefGoogle Scholar
  3. 3.
    R. P. Hill and J. A. Stanley, The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents, Cancer Res. 35:1147 (. 1975 ).PubMedGoogle Scholar
  4. 4.
    J. W. Harris and D. C. Shrieve, Effects of adriamycin and X-rays on euoxic and hypoxic EMTб cells in vitro, Int. J. Radiat. Oncol. Biol. Phys 5:1245 (1979).PubMedCrossRefGoogle Scholar
  5. 5.
    B. A. Teicher, J. S. Lazo and A. C. Sartorelli, Classification of antineoplastic agents by their selective toxicities towards oxygenated and hypoxic cells, Cancer Res. 41: 73 (1981).PubMedGoogle Scholar
  6. 6.
    I. Tannock and P. Guttman, Response of Chinese hamster ovary cells to anti-cancer drugs under aerobic and hypoxic conditions, Br. J. Cancer 43:245 (1981).CrossRefGoogle Scholar
  7. 7.
    E. Smith, I. J. Stratford and G. E. Adams, Cytotoxicity of Adriamycin on aerobic and hypoxic Chinese hamster V79 cells in vitro, Br. J. Cancer 41:568 (1980).CrossRefGoogle Scholar
  8. 8.
    E. Smith, The influence of hypoxia on the cytotoxic response of Chinese hamster cells, Ph.D. Thesis, University of London (1981).Google Scholar
  9. 9.
    W. M. C. Martin and N. J. McNally, Cytotoxicity of Adriamycin to tumour cells in vivo and in vitro, Br. J. Cancer 42: 881 (1980).PubMedCrossRefGoogle Scholar
  10. 10.
    L. Roizin-Towle and E. J. Hall, Studies with Bleomycin and Misonidazole on aerated and hypoxic cells, Br. J. Cancer 37:254 (1978).PubMedCrossRefGoogle Scholar
  11. 11.
    G. E. Adams, К. B. Dawson and I. J. Stratford, Electron-affinie radiation sensitizers for hypoxic cells: prospects and limitations with present and future drugs, in: Proc. Int. Meeting for Radio-Oncology, May 1978, Vienna, Georg Thiéme, Stuttgart:84 (1980).Google Scholar
  12. 12.
    I. J. Stratford, C. Williamson and G. E. Adams, Combination studies with misonidazole and a cis-Platinum complex: Cytotoxicity and Radiosensitization in vitro, Br. J. Cancer 41:517 (1980).PubMedCrossRefGoogle Scholar
  13. 13.
    E. J. Hall and L. Roizin-Towle, Hypoxic sensitizers: Radiobiological studies at the cellular level, Radiology 117: 453 (1975).PubMedGoogle Scholar
  14. 14.
    J. K. Mohindra and A. M. Rauth, Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells, Cancer Res. 36: 930 (1976).PubMedGoogle Scholar
  15. 15.
    A. Moore, B. Palcic and L. D. Skarsgard, Radiosensitizing and toxic effects of the 2-nitroimidazole Ro-07-0582 in hypoxic mammalian cells, Radiat. Res. 67:459 (1976).PubMedCrossRefGoogle Scholar
  16. 16.
    I. J. Stratford and G. E. Adams, The effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensi- tizer, Ro 07-0582, on mammalian cells in vitro, Br. J. Cancer 35:307 (1977).PubMedCrossRefGoogle Scholar
  17. 17.
    R. M. Sutherland, Selective chemotherapy of non-cycling cells in an in vitro tumour model, Cancer Res. 34: 3501 (1974).PubMedGoogle Scholar
  18. 18.
    R. Sridhar, C. Koch and R. M. Sutherland, Cytotoxicity of two nitroimidazole radiosensitizers in an in vitro tumour model, Int. J. Radiat. Oncol. Biol. Phys. 1:1145 (1976).CrossRefGoogle Scholar
  19. 19.
    R. M. Sutherland, The multicellular spheroid system as a tumour model for studies of radiation sensitizers, Pharmac. Ther. 8:105 (1980).Google Scholar
  20. 20.
    J. L. Foster, P. J. Conroy, A. J. Searle and R. L. Willson, Metronidazole (Flagyl): Characterization as a cytotoxic drug specific for hypoxic cells, Br. J. Cancer 33:485 (1976).PubMedCrossRefGoogle Scholar
  21. 21.
    J. M. Brown, Cytotoxic effects of the hypoxic cell radio- sensitizer Ro-07-0582 to tumour cells in vivo, Radiat. Res. 72:469 (1977).PubMedCrossRefGoogle Scholar
  22. 22.
    D. V. Ash, M. R. Smith and R. D. Bugden, Distribution of misonidazole in human tumours and normal tissues, Br. J. Cancer 39:503 (1979).PubMedCrossRefGoogle Scholar
  23. 23.
    C. M. Rose, J. L. Millar, J. H. Peacock, T. A. Phelps and T. C. Stephens, Differential enhancement of melphalan cytotoxicity in tumour and normal tissue by misonidazole, ins “Radiation Sensitizers: Their use in the clinical management of cancer,” Cancer Management Vol. 5, éd., L. W. Brady, Masson, New York (1980) p. 250.Google Scholar
  24. 24.
    J. J. Clement, M. S. Gorman, I. Wodinsky, R. Catane and R. K. Johnson, Enhancement of anti-tumour activity of alkylating agents by the radiation sensitizer misonidazole, Cancer Res. 40: 4165 (1980).PubMedGoogle Scholar
  25. 25.
    I. Tannock, In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: Methotrexate, 5-fluoro- uracil and adriamycin, Br. J. Cancer 42:861 (1980).PubMedCrossRefGoogle Scholar
  26. 26.
    I. Tannock, In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: Cyclophosphamide and BCNU, Br. J. Cancer 42:871 (1980).PubMedCrossRefGoogle Scholar
  27. 27.
    T. C. Stephens, V. D. Courtenay, J. Mills, J. H. Peacock, C. M. Rose and D. Spooner, Enhanced cell killing in Lewis Lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole, Br. J. Cancer 43:451 (1981).PubMedCrossRefGoogle Scholar
  28. 28.
    W. M. C. Martin, N. J. McNally and J. de Ronde, Enhancement of the effect of cytotoxic drugs by radiosensitizers, Br. J. Cancer 43:756 (1981).PubMedCrossRefGoogle Scholar
  29. 29.
    M. P. Law, D. G. Hirst and J. M. Brown, The enhancing effect of misonidazole on the response of the RIF 1 tumour to cyclophosphamide, Br. J. Cancer in press (1981).Google Scholar
  30. 30.
    P. R. Twentyman, Modification of tumour and host response to cyclophosphamide by misonidazole and by WR2721, Br. J. Cancer 43:745 (1981).PubMedCrossRefGoogle Scholar
  31. 31.
    R. T. Mulcahy, D. W. Siemann and R. M. Sutherland, In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU, Br. J. Cancer 43:93 (1981).Google Scholar
  32. 32.
    D. W. Siemann, The in vivo combination of the nitroimidazole misonidazole and the chemotherapeutic agent CCNU, Br. J. Cancer 43:367 (1981).PubMedCrossRefGoogle Scholar
  33. 33.
    R. Clutterbuck, J. L. Millar and T. McElwain, Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts, Cancer Clin. Trials 4: in press (1981).Google Scholar
  34. 34.
    G. E. Adams, C. Clarke, К. B. Dawson, P. W. Sheldon and I. J. Stratford, Nitroimidazoles as hypoxic cell radiation sensitizers and cytotoxic agents, Proc. 2nd Int. Symposium: Biological Bases and Clinical Implications of Tumour Resistance, Rome, Italy, September 21–24 (1980).Google Scholar
  35. 35.
    N. J. McNally, J. Denekamp, P. W. Sheldon, I. R. Flockhart and F. A. Stewart, Radiosensitization by misonidazole (Ro-07-0582): The importance of timing and tumour concentrations, Radiat. Res. 73:568 (1978).PubMedCrossRefGoogle Scholar
  36. 36.
    J. M. Brown and N. Y. Yu, The optimum time for irradiation relative to tumour concentration of hypoxic cell sensitizers, Br. J. Radiol. 53:915 (1980).PubMedCrossRefGoogle Scholar
  37. 37.
    C. J. Gomer and R. J. Johnson, The relationship between misonidazole toxicity and core temperature in C3H mice, Radiat. Res. 78:329 (1979).PubMedCrossRefGoogle Scholar
  38. 38.
    I. J. Stratford, G. E. Adams, M. R. Horsman, S. Kandaiya, S. Rajaratnatii, E. Smith and C. Williamson, The interaction of misonidazole with radiation, chemotherapeutic agents, or heat: A preliminary report, Cancer Clinical Trials 3: 231 (1980).PubMedGoogle Scholar
  39. 39.
    E. Smith, I. J. Stratford and G. E. Adams, Misonidazole enhancement of the cytotoxic action of melphalan in vitro, Br. J. Cancer, submitted (1981).Google Scholar
  40. 40.
    M. E. Varnes, J. E. Biaglow, C. J. Koch and E. J. Hall, Depletion of nonprotein thiols of hypoxic cells by misoni-dazole and metronidazole, in: “Radiation Sensitizers: Their use in the clinical management of cancer,” Cancer Management vol. 5, ed. L. W. Brady, Masson, New York, (1980) p. 121.Google Scholar
  41. 41.
    T. A. Conners, Protection against the toxicity of alkylating agents by thiols: The mechanism of protection and its relevance to cancer chemotherapy - a review, Eur. J. Cancer 2:293 (1966).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • I. J. Stratford
    • 1
  • G. E. Adams
    • 1
  1. 1.Institute of Cancer ResearchSutton, SurreyUK

Personalised recommendations